Pediatric migraine Theranica’s Nerivio REN wearable targets pediatric and adolescent migraine patients, a large and underserved segment. Sales opportunities exist in hospitals, pediatric neurology clinics, school-based health programs, and telemedicine partnerships that emphasize non-drug, safe, and early-intervention therapy.

Non-drug treatment The FDA-cleared, drug-free neuromodulation solution positions Theranica well for payers and providers seeking alternatives to medications with side effects. Messaging and proposals can focus on reducing prescription drug use, adverse events, and downstream healthcare costs linked to migraine management.

Clinical validation With real-world and conference exposure, including CNS meeting participation and prior awards, there is momentum for expanding post-market studies, payerEvidence, and clinician education programs. Opportunities exist to sponsor or co-develop reimbursement-focused studies to strengthen clinician adoption.

Global reach Nerivio has regulatory clearances (FDA and CE) and a broad patient base in the US, suggesting market-entry opportunities in international markets through distributors, regional partners, or direct commercial teams, especially in markets with rising adolescent migraine prevalence.

Strategic partnerships Theranica’s tech stack and scalable hardware platform enable potential collaborations with telehealth providers, pediatric care networks, veteran health programs, and school health entities. Proposing bundled solutions with remote monitoring, clinician dashboards, and outcome data could drive integrated care deals.